Prognostic and therapeutic significance of carbohydrate antigen 19-9 as tumor marker in patients with pancreatic cancer

被引:147
作者
Boeck, Stefan
Stieber, Petra
Holdenrieder, Stefan
Wilkowski, Ralf
Heinemann, Volker
机构
[1] Univ Munich, Klinikum Grosshadern, Dept Internal Med 3, DE-81377 Munich, Germany
[2] Univ Munich, Klinikum Grosshadern, Inst Clin Chem, D-8000 Munich, Germany
[3] Univ Munich, Klinikum Grosshadern, Dept Radiooncol, D-8000 Munich, Germany
关键词
pancreatic cancer; tumor marker; carbohydrate antigen 19-9;
D O I
10.1159/000094888
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In pancreatic cancer ( PC) accurate determination of treatment response by imaging often remains difficult. Various efforts have been undertaken to investigate new factors which may serve as more appropriate surrogate parameters of treatment efficacy. This review focuses on the role of carbohydrate antigen 19- 9 ( CA 19- 9) as a prognostic tumor marker in PC and summarizes its contribution to monitoring treatment efficacy. We undertook a Medline/ PubMed literature search to identify relevant trials that had analyzed the prognostic impact of CA 19- 9 in patients treated with surgery, chemoradiotherapy and chemotherapy for PC. Additionally, relevant abstract publications from scientific meetings were included. In advanced PC, pretreatment CA 19- 9 levels have a prognostic impact regarding overall survival. Also a CA 19- 9 decline under chemotherapy can provide prognostic information for median survival. A 20% reduction of CA 19- 9 baseline levels within the first 8 weeks of chemotherapy appears to be sufficient to define a prognostic relevant subgroup of patients ('CA 19- 9 responder'). It still remains to be defined whether the CA 19- 9 response is a more reliable method for evaluating treatment efficacy compared to conventional imaging. Copyright (c) 2006 S. Karger AG, Basel.
引用
收藏
页码:255 / 264
页数:10
相关论文
共 65 条
  • [11] Modern management of pancreatic carcinoma
    Goldstein, D
    Carroll, S
    Apte, M
    Keogh, G
    [J]. INTERNAL MEDICINE JOURNAL, 2004, 34 (08) : 475 - 481
  • [12] Halm U, 2000, BRIT J CANCER, V82, P1013
  • [13] Heinemann V, 1999, ANTICANCER RES, V19, P2433
  • [14] Gemcitabine in the treatment of advanced pancreatic cancer: A comparative analysis of randomized trials
    Heinemann, V
    [J]. SEMINARS IN ONCOLOGY, 2002, 29 (06) : 9 - 16
  • [15] Present and future treatment of pancreatic cancer
    Heinemann, V
    [J]. SEMINARS IN ONCOLOGY, 2002, 29 (03) : 23 - 31
  • [16] Ikeda W, 2001, CANCER-AM CANCER SOC, V91, P490, DOI 10.1002/1097-0142(20010201)91:3<490::AID-CNCR1027>3.0.CO
  • [17] 2-L
  • [18] Ishii H, 1997, HEPATO-GASTROENTEROL, V44, P279
  • [19] Systemic inflammatory response predicts outcome in patients undergoing resection for ductal adenocarcinoma head of pancreas
    Jamieson, NB
    Glen, P
    McMillan, DC
    McKay, CJ
    Foulis, AK
    Carter, R
    Imrie, CW
    [J]. BRITISH JOURNAL OF CANCER, 2005, 92 (01) : 21 - 23
  • [20] Jiang Xiao-Ting, 2004, Hepatobiliary Pancreat Dis Int, V3, P464